Kinvard Bio

Overview

Kinvard Bio is developing a differentiated lincosamide class of antibiotics, the oxepanoprolinamides (OPPs), based on research from the Myers lab in the Department of Chemistry and Chemical Biology at Harvard University. The OPP class is highly potent against multidrug-resistant gram positive and gram-negative bacteria, overcoming resistance to currently approved antibiotics. Kinvard Bio’s focus is on infections representing significant global health burden and high unmet need such as complicated urinary tract infections (cUTI), community-acquired bacterial pneumonia (CABP), hospital acquired / ventilator acquired bacterial pneumonia (HABP/VABP) and nontuberculosis mycobacteria lung disease (NTM-LD).